Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06464991
Other study ID # CT103AC004
Secondary ID
Status Recruiting
Phase Phase 3
First received
Last updated
Start date March 27, 2024
Est. completion date December 2030

Study information

Verified date June 2024
Source Nanjing IASO Biotechnology Co., Ltd.
Contact Yue Wan
Phone +86 025-58287610
Email yue.wan@iasobio.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a multicenter, randomized, controlled, open-label, phase III clinical study to evaluate the efficacy of Equecabtagene Autoleucel Injection versus standard therapy in subjects with lenalidomid-refractory RRMM who have received 1-2 lines of prior therapy.


Description:

Multiple myeloma (MM) is a malignant neoplasm of plasma cells that accounts for more than 10%-20% of hematologic malignancies worldwide, leading to marrow failure and bone destruction. Equecabtagene Autoleucel (eque-cel) is an autologous chimeric antigen receptor T-cell (CAR-T) therapy that targets B-cell maturation antigen (BCMA), which expressed on both mature B lymphocytes and malignant plasma cells. The primary objective for this study is to compare the efficacy of eque-cel versus standard therapy in lenalidomid-refractory RRMM. Subjects will undergo screening with informed consent. After enrollment, randomization will be conducted followed by study treatment in experimental or control group. A follow-up phase will include assessments for safety, efficacy evaluation and pharmacokinetics monitoring (experimental arm) . The duration of this trial is about 6 years.


Recruitment information / eligibility

Status Recruiting
Enrollment 240
Est. completion date December 2030
Est. primary completion date August 2027
Accepts healthy volunteers No
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria: 1.18 to 70 years of age (inclusive of cutoff), regardless of gender. 2. Subjects were previously diagnosed with multiple myeloma and received 1-2 lines of proteasome inhibitor and immunomodulatory-based chemotherapy, with at least one complete cycle of each line of treatment; Documented disease progression during or within 12 months after the most recent anti-myeloma therapy. 3. Subjects were previously refractory to lenalidomide treatment. 4.ECOG score of 0 or 1. 5. Subjects must have adequate organ function and meet all the following laboratory test results before enrollment: ? Blood routine: absolute neutrophil count (ANC) =1×10^9/L (growth factor support allowed, but no supportive treatment within 7 days before laboratory test); Absolute lymphocyte count (ALC) =0.3×10^9/L; Platelet count =50×10^9 / L (no supportive platelets infusion allowed within 7 days before lab test ); Hemoglobin =60g/L (no transfusion of red blood cells [RBC] within 7 days before the laboratory test; the use of recombinant human erythropoietin was allowed); (2) liver function: alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =2.5 times of upper limit of normal (ULN); Serum total bilirubin =1.5 times of ULN; (3) renal function according to Cockcroft - Gault formula of creatinine clearance (CrCl) should be =40 ml/min; ? Coagulation function: fibrinogen =1.0g/L; aPTT=1.5 x ULN, prothrombin time (PT)=1.5 x ULN; ? oxygen saturation>91%; ? Left ventricular ejection fraction (LVEF) =50%. 6. Subjects agree to use effective tools or drug contraception (excluding safe period contraception) after signing the informed consent form. 7. Before starting any screening program, subjects must have to agreed to sign or sign the informed consent in person which have been approved by the ethics committee. Exclusion Criteria: 1. Subjects who have used or need long-term use of immunosuppressive agents, such as cyclosporine or systemic steroid) 14days before enrollment; but the use of physiological substitute, intermittent, local and inhaled steroids is allowed. 2. Patients who had undergone autologous hematopoietic stem-cell transplantation (Auto-HSCT) within 12 weeks before randomization or prior allogeneic hematopoietic stem-cell transplantation (Allo-HSCT); 3. The subject received the following anti-tumor therapy before enrollment: ? immunomodulatory therapy within 7 days, or; ? Plasma exchange, radiotherapy (except for local radiotherapy for myeloma-associated bone lesions), cytotoxic chemotherapy, proteasome inhibitor, or other investigation drug in clinical trial within 14 days; or (3) monoclonal antibody treatment for multiple myeloma within 21 days, or; (4) within 14 days or at least five half-life (will be subject to a shorter time) of other anti-tumor treatment except for the above-mentioned ones; 4. Severe heart disease; 5. Unstable Systemic diseases per investigator's evaluation: including, but not limited to, severe hepatic, renal, or metabolic diseases requiring medical treatment; 6. subjects with the following conditions per investigator's evaluation will not be able to participate in the study: (1) allergic to excipients of Equecabtagene Autoleucel Injection (DMSO and albumin), fludarabine, cyclophosphamide, tocilizumab, or; ? subjects intolerant to dexamethasone, or; (3) subjects who have life-threatening allergy, allergic reactions, or intolerance (intolerance is defined as end of treatment for any pomalidomide related AE) with pomalidomide, or; ? subjects who met the NCI-CTCAE v5.0 definition of grade 2 peripheral neuropathy with pain or = grade 3 peripheral neuropathy; 7. Diagnosed with another malignancy within 5 years before screening except for multiple myeloma, excluding radical cervical carcinoma in situ, basal cell or squamous epithelial cell skin cancer, radical localized prostate cancer, radical ductal carcinoma in situ of the breast, or papillary thyroid cancer; 8. Patients with suspected or existed central nervous system involvement of plasma cell neoplasms during screening; 9. subjects with plasma cell leukemia (defined as > 5% peripheral plasma cells), Waldenstrom macroglobulinemia, POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and cutaneous changes), or primary amyloidosis previously or during screening period; 10. Multiple myeloma patients with extramedullary lesions (except for a single parosteal extramedullary lesion =3cm in maximum transverse diameter) 11. Subject who underwent major surgery within 2 weeks before randomization or have surgery plan within 2 weeks after study treatment (except for those scheduled surgery under local anesthesia); 12. Subject with uncontrollable infection; 13. The hepatitis b surface antigen (HBsAg) or hepatitis b core antibody (HBcAb) positive with hepatitis b virus (HBV) DNA quantification higher than the detection limit; Hepatitis C virus (HCV) antibody positive with HCV RNA positive in peripheral blood; human immunodeficiency virus (HIV) antibody positive; Syphilis testing positive; 14. Women who are pregnant or lactating; 15. The subject has a existed central nervous system disease or with medical history of CNS disease; 16. Non-hematologic toxicity due to prior therapy havn't been resolved to baseline or = grade 1 (NCI-CTCAE version 5.0, excluding alopecia and grade 2 peripheral neuropathy) 17. The subject had other conditions unsuitable for enrollment per investigator's evaluation.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Equecabtagene Autoleucel Injection
dosage form: injection, dosage: 1.0×10^6 CAR-T/kg, frequency: single dose.
Daratumumab
dosage form: Injection dose level:16mg/kg frequency: 28days/cycle for DPd regimen Cycle1-2:D1, D8, D15, D22; Cycle3-6:D1, D15; above Cycle7:D1
Pomalidomide
dosage form:capsule. doseage form: capsule. dose level: 4mg/d. frequency: every cycle: D1-D21 for DPd regimen, D1-D14 for PVd regimen.
Bortezomib
dosage form: subcutaneous injection. dose level: 1.3mg/m2. frequency: 21days/cycle for PVd regimen cycle 1-8: D1,D4, D8, D11; above cycle 9: D1, D8.
Dexamethasone
dosage form: oral or intravenus injection. dose level:20mg/d. frequency: for DPd: every cycle, D1, D2, D8, D9, D15, D16, D22, D23; for PVd: Cycle1-8:D1, D2, D4, D5, D8, D9, D11, D12; above Cycle 9: D1, D2, D8, D9.

Locations

Country Name City State
China Beijing Chao-Yang Hospital, Capital Medical University Beijing
China Peking Union Medical College Hospital Beijing
China Peking University First Hospital Beijing
China Peking University Third Hospital Beijing
China People's Hospital of Peking University Beijing
China The first hospital of Jilin University Chang chun
China West China School of Medicine, West China Hospital of Sichuan University Chengdu
China Xinqiao Hospital of AMU Chongqing
China Nanfang Hospital, Southern Medical University Guangzhou
China Sun Yat-sen University Cancer Centre Guangzhou
China Zhujiang Hospital of Southern Medical University Guangdong Guangzhou
China The First Affiliated Hospital, College of Medicine, Zhejiang University Hangzhou Zhejiang
China The Second Affiliated Hospital,Zhejiang University School of Medicine Hangzhou
China Qilu Hospital of Shangdong University Jinan
China The First Affiliated Hospital of Nanchang University Nanchang
China Affiliated Drum Tower Hospital, Medical School of Nanjing University Nanjing
China Jiangsu Province Hospital Nanjing
China The Affiliated People's Hospital of Ningbo University Ningbo
China Ruijin Hospital, Shanghai Jiaotong University School of Medicine Shanghai
China The First Affiliated Hospital of Soochow University Suzhou
China Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences Tianjing
China Tianjin Medical University General Hospital Tianjing
China The First Affiliated Hospital of Wenzhou Medical University Wenzhou
China Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology Wuhan
China Union Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology Wuhan
China Henan Cancer Hospital Affilated Cancer Hospital of Zhengzhou University Zhengzhou

Sponsors (1)

Lead Sponsor Collaborator
Nanjing IASO Biotechnology Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Progression Free Survival per independent review committee, PFS per IRC The time from randomization to the first time of documented disease progression or death from any cause per IRC up to 5 years from randomization
Secondary Minimal Residual Disease Negativity Rate Proportion of subjects with MRD-negative bone marrow detection by next-generation flow cytometry following study therapy up to 5 years from randomization
Secondary Duration of MRD negativity The time from the first MRD negative to the first MRD negative positive transfer up to 5 years from randomization
Secondary Complete Response rate Proportion of subjects who achieved CR or better response after receiving study therapy up to 5 years from randomization
Secondary Rate of very good partial response or better Proportion of subjects who achieved strict complete response (sCR), CR, and VGPR after receiving study therapy up to 5 years from randomization
Secondary Overall Response Rate Proportion of subjects who achieved sCR, CR, VGPR, and PR after receiving study therapy up to 5 years from randomization
Secondary Event Free Survival The time from the start of randomization until the first occurrence of any of the following events, including death, disease progression, change of treatment, addition of another treatment, fatal or intolerable side effects up to 5 years from randomization
Secondary Overall Survival The time from randomization until death from any cause up to 5 years from randomization
Secondary Time to Next Treatment The time from receipt of the trial drug to initiation of the next line of treatment up to 5 years from randomization
Secondary incidence of Adverse events Safety Endpoint up to 5 years from randomization
Secondary Pharmacokinetic Endpoint-Cmax The maximum concentration (Cmax) of CAR VCN and BCMA CAR-T in peripheral blood after CAR-T infusion up to 5 years from Eque-cel infusion
Secondary Pharmacokinetic Endpoint-Tmax the time for CAR VCN and BCMA CAR-T to reach the maximum concentration (Tmax) after CAR-T infusion up to 5 years from Eque-cel infusion
Secondary Pharmacokinetic Endpoint-AUC Area under the curve of 29, 85, 169 days and the last time point of PK detection (AUC0-29d, AUC0-85d, AUC0-169d, AUC0-last) for CAR VCN; Area under the curve of 29 days (AUC0-29) for BCMA CAR-T. up to 5 years from Eque-cel infusion
Secondary Pharmacodynamic Endpoint The concentration of soluble BCMA in peripheral blood of experimental group at each time point up to 5 years from Eque-cel infusion
Secondary Health Related Quality of Life Endpoint Symptoms, function, and overall HRQoL were collected using the validated Patient-Reported Outcomes (PRO) questionnaire up to 5 years from randomization
See also
  Status Clinical Trial Phase
Recruiting NCT05027594 - Ph I Study in Adult Patients With Relapsed or Refractory Multiple Myeloma Phase 1
Completed NCT02412878 - Once-weekly Versus Twice-weekly Carfilzomib in Combination With Dexamethasone in Adults With Relapsed and Refractory Multiple Myeloma Phase 3
Completed NCT01947140 - Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies Phase 1/Phase 2
Recruiting NCT05971056 - Providing Cancer Care Closer to Home for Patients With Multiple Myeloma N/A
Recruiting NCT05243797 - Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation Phase 3
Active, not recruiting NCT04555551 - MCARH109 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of Multiple Myeloma Phase 1
Recruiting NCT05618041 - The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies N/A
Active, not recruiting NCT03844048 - An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial Phase 3
Recruiting NCT03412877 - Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer Phase 2
Completed NCT02916979 - Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATG Phase 1
Recruiting NCT03570983 - A Trial Comparing Single Agent Melphalan to Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) as a Preparative Regimen for Patients With Multiple Myeloma Undergoing High Dose Therapy Followed by Autologous Stem Cell Reinfusion Phase 2
Terminated NCT03399448 - NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells) Phase 1
Completed NCT03665155 - First-in- Human Imaging of Multiple Myeloma Using 89Zr-DFO-daratumumab, a CD38-targeting Monoclonal Antibody Phase 1/Phase 2
Completed NCT02812706 - Isatuximab Single Agent Study in Japanese Relapsed AND Refractory Multiple Myeloma Patients Phase 1/Phase 2
Active, not recruiting NCT05024045 - Study of Oral LOXO-338 in Patients With Advanced Blood Cancers Phase 1
Active, not recruiting NCT03792763 - Denosumab for High Risk SMM and SLiM CRAB Positive, Early Myeloma Patients Phase 2
Active, not recruiting NCT03989414 - A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM) Phase 1/Phase 2
Withdrawn NCT03608501 - A Study of Ixazomib, Thalidomide and Dexamethasone in Newly Diagnosed and Treatment-naive Multiple Myeloma (MM) Participants Non-eligible for Autologous Stem-cell Transplantation Phase 2
Recruiting NCT04537442 - Clinical Study to Evaluate the Safety and Efficacy of IM21 CAR-T Cells in the Treatment of Elderly Patients With Relapsed or Refractory Multiple Myeloma Phase 1
Completed NCT02546167 - CART-BCMA Cells for Multiple Myeloma Phase 1